SFDA Economic Evaluation Studies: Building a Budget Impact Model for Saudi Arabia (2026)
Saudi Arabia’s healthcare market is scaling fast under Vision 2030, but formulary and tender decisions are increasingly governed by disciplined budget-impact reasoning rather than clinical narrative alone. For pharmaceutical and biotech teams preparing SFDA economic evaluation submissions, the practical question is whether a budget impact model Saudi Arabia approach is enough—and if so, how to make it locally credible enough for NUPCO, MOH, and hospital pharmacy & therapeutics committees.
This guide focuses on building a defensible budget impact model for the Saudi context: the data inputs reviewers expect, the difference between BIA and full pharmacoeconomic evaluation, common failure modes, and how to move from generic global templates to KSA-specific scenarios. For broader context on payer and regulatory mechanics, see SFDA market access strategy, the GCC market access guide, and Saudi Arabia healthcare market research.
Why budget impact analysis is now central to Saudi market access
Three forces are elevating budget impact analysis in KSA:
- SFDA economic evaluation expectations — SFDA’s July 2024 EES guidance reinforces the need for payer-relevant economic evidence, especially for high-cost or novel therapies entering the formulary system.
- NUPCO and tender discipline — Centralized procurement wants defensible budget trajectories, annual cohort growth, and scenario discipline before new products are listed.
- Hospital committees — pharmacists, clinicians, and finance leads now expect budget scenarios before formularies shift, particularly in ophthalmology, oncology, rare disease, and immunology.
Budget impact analysis is therefore not an optional appendix: it is negotiation infrastructure that determines whether a product gets listed, tendered, and adopted at scale.
What SFDA requires in a budget impact model
SFDA reviewers typically expect budget impact models to reflect the payer perspective, with clarity on:
- Time horizon — 3–5 years is standard, with yearly cohort updates tied to uptake assumptions.
- Comparator choice — Active comparators should mirror current Saudi prescribing, not European reference cases.
- SAR costing — Use locally sourced acquisition costs, administration overhead, and monitoring assumptions.
- Sensitivity analysis — Deterministic and probabilistic sensitivities on price, uptake, and discontinuation improve committee confidence.
When comparator benefit is already established, BIA is often accepted alongside—rather than replaced by—a full cost-effectiveness analysis. For high-cost therapies, however, committees may ask for both BIA and CEA/CUA depth to assess incremental value.
Data inputs that make models credible in KSA
A model is only as credible as its epidemiology, market-share logic, and treatment-pathway assumptions. Reviewers in Riyadh, Jeddah, and Dammam respond poorly to EU-transposed assumptions.
Credible inputs include: national or regional incidence and prevalence data where available; treatment pathways mapped to local hospital formularies; market-share transitions tied to expected launch timing; and consumption data from claims or panel audits. Avoid placeholder comparators, outdated price references, or treatment patterns that no longer match real-world prescribing.
Hospital consumption data is particularly persuasive when the budget-impact question is framed around tender or formulary volume. For teams without primary local data, advisory-board style primary research can bridge the gap between global estimates and committee-grade scenario planning.
Budget impact vs full pharmacoeconomic evaluation
Budget impact analysis answers the affordability question: what happens to payer budgets if uptake follows a realistic adoption curve. Full pharmacoeconomic evaluation, including cost-effectiveness analysis and cost-utility analysis, answers the value question: is the therapy worth its price relative to standard care.
In Saudi Arabia, the BIA is usually the more immediate requirement for formulary and tender contexts, while CEA/CUA depth becomes necessary when price negotiations are contentious or when NUPCO requires incremental-value justification for premium-priced therapies.
NUPCO and formulary committee review
NUPCO and hospital P&T committees use budget impact models to test affordability across procurement cycles. Models should therefore include:
- Year-by-year budget trajectories
- Comparator retention and switching assumptions
- Scenario A/B/C overlays on uptake and price
- Clear presentation suitable for non-health-economist committee members
Committees reward models that tie directly to existing treatment guidelines or formulary sections, not abstract global assumptions. Translation into Arabic-ready summaries and dashboard-friendly outputs can accelerate acceptance.
Common failure modes
- Generic global templates — Models that transplant EU epidemiology without Saudi context lose credibility immediately.
- Wrong comparator — Using therapies not prescribed locally undermines the entire scenario.
- Missing Arabic stakeholder summaries — Committees with lay or Arabic-first members expect narrative summaries in addition to Excel workbooks.
- Single-point price algebra — Committees want sensitivities and rebate scenarios, not list-price certainty claims.
How BioNixus supports BIM and HEOR in Saudi Arabia
BioNixus supports Saudi budget-impact modelling with payer panels, hospital consumption data, local epidemiology, and dossier rehearsal for SFDA-facing economic evaluation submissions. Our teams combine quantitative modelling with qualitative committee prep so budget-impact arguments are grounded in real prescribing and procurement reality rather than disconnected spreadsheet exercises. To discuss HEOR support, contact BioNixus or explore Saudi healthcare market research.
FAQ
Does SFDA require a full pharmacoeconomic evaluation for every product?
No. SFDA guidance allows a standalone budget impact model when the comparative effectiveness component is already established or when the dossier purpose is formulary/tender readiness rather than first-in-class price setting.
What time horizon do Saudi payers expect in a budget impact model?
Most committees accept 3–5 year horizons, with annual cohort refresh and sensitivity overlays on uptake curves and net price assumptions.
Should I reuse epidemiology from European reference cases for KSA models?
Avoid direct reuse. Local epidemiology, treatment pathways, and hospital consumption patterns differ materially from EU assumptions and weaken credibility in SFDA and NUPCO review.
How important is Arabic-language stakeholder output?
Arabic summaries for formulary committees are increasingly expected, especially where lay-member reviewers participate or payer communications are bilingual.
When should budget impact planning start for a Saudi launch?
Start at least 18–24 months before anticipated listing or tender windows so model inputs can be validated with local KOLs and hospital data.